Core Viewpoint - The collaboration between Innovent Biologics and Eli Lilly marks the seventh partnership since 2015, focusing on the global development of innovative drugs in oncology and immunology, showcasing Innovent's strong R&D capabilities recognized by multinational corporations [1] Event - On February 8, Innovent Biologics announced a strategic partnership with Eli Lilly to advance the global development of innovative drugs in oncology and immunology, with Innovent leading the projects from drug discovery to clinical concept validation in China [1] Financial Details - The collaboration includes an upfront payment of $350 million and a total package worth $8.85 billion, with Innovent retaining all rights in Greater China while Eli Lilly obtains exclusive global development and commercialization rights outside this region [1] - Innovent is eligible for up to approximately $8.5 billion in milestone payments related to R&D, regulatory, and commercialization, along with a tiered sales share from net sales outside Greater China [1] R&D Capacity - The partnership indicates high recognition of Innovent's early-stage R&D and concept validation capabilities in oncology and immunology by Eli Lilly, which has a strong portfolio in these areas [2] - Innovent has 17 commercialized drugs, with one product under NMPA review, four new drug molecules in Phase III or critical clinical studies, and 15 additional new drug candidates in clinical research [2] Profit Forecast and Investment Recommendation - Innovent's extensive layout in oncology is expected to enhance revenue and reduce marginal costs, while the company also has competitive products in metabolic, autoimmune, and ophthalmology fields [2] - A global strategic partnership with Takeda, valued at $11.4 billion, is anticipated to accelerate the introduction of next-generation IO and ADC therapies to the global market, marking a significant step in Innovent's internationalization [2] - Revenue projections for Innovent from 2025 to 2027 are estimated at 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan respectively [2] - The company’s reasonable market value is estimated at 232.7 billion HKD, with a target price set at 136.12 HKD, maintaining a "buy" rating [2]

2026.02. 10 本文字数：855，阅读时长大约2分钟 作者 | 第一财经 钱童心 2月10日，阿斯利康公布2025年第四季度及全年财报。2025年，阿斯利康全球总营收达587.39亿 美元，同比增长8%，其中阿斯利康中国2025年总营收达66.54亿美元，同比增长4%，占总收入比 约11%，生物制药、肿瘤、罕见病三大业务领域均实现增长。 阿斯利康预测，2026年利润和销售将继续增长，这主要得益于癌症治疗和新药的需求。去年第四季 度，阿斯利康肿瘤药业务增长20%至70.3亿美元，但心血管业务受仿制药竞争影响下跌6%至30.5 亿美元。 阿斯利康CEO苏博科（Pascal Soriot）表示，2025年，阿斯利康宣布了16项积极的三期研究结 果，目前共有16种畅销药物。他还表示，公司今年预计还将公布超过20项三期试验结果，且还有 100多项三期临床试验正在进行中，包括多种创新技术疗法。 阿斯利康的目标是到2030年，年度销售额达到800亿美元，这一目标的实现将通过开发新药物和进 行投资来实现。公司计划到2030年推出20款全球创新药。 为此，阿斯利康正在推动在美国和中国的扩张。上个月，阿斯利康宣布从现在到 ...

证券日报网2月9日讯，西藏药业（600211）在接受调研者提问时表示，锐正基因主要在研产品：针对转 甲状腺素蛋白淀粉样变性(ATTR)的产品ART001，于去年分别获批中国和美国IND(新药临床研究审 批)，目前在中国正在开展I/IIa期临床试验；以PCSK9(前蛋白转化酶枯草溶菌素9)为靶点的产品 ART002，目前正在开展针对家族性高胆固醇血症的IIT临床研究，该在研产品尚未取得临床批件。后期 研发费用投入随研发进展调整。 ...

每经AI快讯，2月8日，信达生物在港交所发布公告，公司连同其附属公司信达生物制药(苏州)有限公 司、Fortvita Biologics (Singapore) Pte. Ltd, Fortvita Biologics Inc.及Fortvita Biologics (USA), Inc.与礼来公 司达成战略合作，携手推进肿瘤及免疫领域创新药物的全球研发。本次协议为双方第七次合作，进一步 深化了双方长期且富有成效的合作伙伴关系，携手为全球患者带来创新药物。这一独特的合作架构也为 公司打造了全新的合作模式，加速公司创新研发管线的全球化开发进程。 ...

Core Insights - The article discusses significant advancements in hypertension treatment, focusing on new drug developments and their implications for clinical practice [1][19]. Group 1: Shifts in Treatment Focus - The focus of hypertension drug development has shifted from "resistant hypertension" to "uncontrolled hypertension," allowing for earlier intervention in treatment [1][2]. Group 2: Key Drug Developments - Four major advancements in hypertension treatment are highlighted: 1. **Aldosterone Synthase Inhibitors**: New second-generation inhibitors like Lorundrostat and Baxdrostat show promising clinical results, significantly lowering blood pressure in patients [2][3][7]. 2. **Angiotensinogen Inhibitors**: Utilizing innovative technologies such as siRNA, drugs like Zilebesiran demonstrate effective long-term blood pressure control [9][10]. 3. **Dual Endothelin Receptor Antagonists**: Aprocitentan, recently approved by the FDA, effectively treats resistant hypertension with a balanced receptor inhibition approach [12][13][16]. 4. **Hypertension Vaccine**: The HJY-ATRQβ-001 vaccine, recently approved for clinical trials, represents a novel long-term treatment option for hypertension [17][18]. Group 3: Clinical Implications - The advancements in drug development not only address existing clinical challenges but also reflect a deeper integration of basic research into clinical applications, promising more effective and safer treatment options for hypertension management [19].

Group 1 - The core point of the article is that Sinopharm has announced a strategic collaboration with Eli Lilly to develop new drugs in oncology and immunology on a global scale [1] Group 2 - The partnership aims to leverage both companies' strengths in research and development to accelerate the discovery and commercialization of innovative therapies [1] - This collaboration signifies a growing trend in the pharmaceutical industry where companies are increasingly forming alliances to enhance their drug development capabilities [1] - The focus on oncology and immunology reflects the rising demand for advanced treatments in these therapeutic areas, which are critical for addressing significant health challenges [1]

证券日报网讯2月8日，京新药业（002020）在互动平台回答投资者提问时表示，公司的降脂新药 PL(a)JX2201的临床I期接近尾声。 ...

Core Viewpoint - The company is expected to achieve a product revenue of approximately 11.9 billion yuan in 2025, maintaining a strong year-on-year growth rate of about 45% [1] - In Q4, the company achieved a product revenue of around 3.3 billion yuan, with a year-on-year increase of over 60%, validating its strong product competitiveness and commercialization system [1] - The growth is driven by the sustained performance of existing products and rapid market entry of new products, with significant contributions from non-oncology areas [1] Event Summary - On February 4, the company announced its product revenue for 2025, projecting around 11.9 billion yuan for the year and approximately 3.3 billion yuan for Q4 [1] - The Q4 revenue was influenced by the inclusion of six new drugs in the national medical insurance catalog, which led to a one-time inventory adjustment [1] Business Performance - The company has expanded its oncology pipeline to 13 products, demonstrating increasing synergy effects [2] - The successful expansion into chronic disease areas has resulted in outstanding achievements, showcasing strong growth potential across its product line [2] - Key growth drivers include products like Sintilimab, Orelabrutinib, and Lembozole, along with rapid market entry of new products such as Masitinib and Tolebrutinib [1][2] Future Outlook - The company is expected to continue leveraging its core advantages and strategic foresight to drive development across multiple disease areas, aiming to become a leading global biopharmaceutical company [2] - The company has 17 commercialized drugs, with one product under NMPA review and four new drug candidates in Phase III or critical clinical studies, alongside 15 other candidates in clinical research [2] Financial Projections - The company is projected to achieve revenues of 11.968 billion yuan, 22.804 billion yuan, and 26.572 billion yuan for the years 2025, 2026, and 2027, respectively, with net profits of 0.886 billion yuan, 6.679 billion yuan, and 8.004 billion yuan [2] - Following a significant global strategic partnership with Takeda, the company retains 40% rights in the U.S. for IBI363, which is expected to enhance its internationalization efforts [2]

Core Viewpoint - Biogen's forecast for 2026 profits exceeds Wall Street's average expectations, indicating that significant cost-cutting measures are mitigating the impact of declining sales from its multiple sclerosis (MS) products [1][3]. Financial Performance - Biogen reported Q4 2025 total revenue of approximately $2.279 billion, a year-over-year decline of 7%, but still above Wall Street expectations. Adjusted earnings per share (EPS) were $1.99, also exceeding analyst forecasts [4]. - For the full year 2025, total revenue reached $9.891 billion, reflecting a 2% year-over-year increase, with adjusted EPS at $15.28, down 7% year-over-year, both surpassing Wall Street expectations [4]. - The company anticipates a mid-single-digit percentage decline in overall revenue for 2026, continuing the operational pressure on its MS treatment business [3][4]. Product Performance and Pipeline - The revenue from new drugs, particularly Leqembi, is crucial for Biogen's growth. In 2025, combined revenue from Leqembi, Skyclarys, Zurzuvae, and Qalsody approached $1 billion [4]. - Leqembi's sales in Q4 2025 were approximately $134 million, up from $121 million in the previous quarter, but growth is constrained by systemic bottlenecks in the healthcare system [5][7]. - Biogen is focusing on reducing reliance on neuroscience by enhancing its rare disease portfolio through acquisitions and shifting research emphasis towards immunology [6][9]. Strategic Initiatives - CEO Chris Viehbacher has implemented strict cost discipline, including job cuts and the removal of certain drugs from the development pipeline, to support new product growth [7]. - The company is seeking FDA approval for a subcutaneous administration of Leqembi, which could improve accessibility and differentiate it from competitors [9]. - Biogen is also awaiting key trial data for several experimental drugs, including a new Alzheimer's treatment and litifilimab for lupus, which could further diversify its product offerings [10].

消息面上，诺诚健华此前发布业绩预告，预计2025年实现收入23.7亿元，同比增长约134%；预计2025 年归母净利润首次扭亏为盈，达6.3亿元左右。核心产品奥布替尼贡献显著增量，2025年5月坦昔妥单抗 获批上市后进一步丰富药品收入来源。全年达成的两项BD交易亦是2025年营业收入快速增长的另一个 重要因素。 值得注意的是，诺诚健华宣布，公司自主研发的新型TYK2抑制剂ICP-488治疗银屑病的III期临床试验已 完成患者入组，总共入组383例患者。这标志着ICP-488治疗银屑病取得重大临床进展，有望为银屑病患 者带来新的口服治疗选择。这项临床试验为多中心、随机、双盲、安慰剂对照，旨在评价ICP-488单药 治疗中重度斑块状银屑病成人患者的有效性和安全性。 诺诚健华(09969)早盘涨超4%，截至发稿，涨3.95%，报11.83港元，成交额3869.91万港元。 ...